AnaptysBio Inc. is a clinical-stage biotechnology company focused on developing innovative antibody product candidates for immunology and inflammatory diseases. It advances a pipeline including imsidolimab, a fully human monoclonal antibody targeting the IL-36 receptor for conditions like generalized pustular psoriasis; ANB030, an anti-IL-33 antibody for atopic dermatitis and other allergic diseases; and rosnilimab, a PD-1 agonist designed to induce immune checkpoint signaling for autoimmune disorders such as rheumatoid arthritis and ulcerative colitis. The company also receives royalties from Jemperli, its anti-PD-1 antibody partnered with GSK for oncology indications. AnaptysBio Inc. leverages its proprietary SHM platform, which mimics the natural somatic hypermutation process in the human immune system to engineer high-affinity, therapeutic-grade antibodies in vitro. Headquartered in San Diego, California, and founded in 2005, it plays a key role in the biopharma sector by addressing unmet needs in immune-mediated diseases through differentiated antibody therapies.